Urispas: Effective Relief for Bladder Spasms and Urinary Urgency
Urispas
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.60 | $48.00 (0%) | 🛒 Add to cart |
| 60 | $1.30 | $96.00 $78.00 (19%) | 🛒 Add to cart |
| 90 | $1.21 | $144.00 $109.00 (24%) | 🛒 Add to cart |
| 120 | $1.16 | $192.00 $139.00 (28%) | 🛒 Add to cart |
| 180 | $1.12 | $288.00 $201.00 (30%) | 🛒 Add to cart |
| 270 | $1.09 | $432.00 $294.00 (32%) | 🛒 Add to cart |
| 360 | $1.07
Best per pill | $576.00 $385.00 (33%) | 🛒 Add to cart |
Synonyms | |||
Urispas (generic name: flavoxate hydrochloride) is an antispasmodic medication specifically formulated to target and relieve symptoms associated with urinary tract conditions. It works by relaxing the smooth muscles of the urinary bladder, thereby reducing spasms, urgency, frequency, and discomfort during urination. This medication is commonly prescribed for patients experiencing overactive bladder, cystitis, or other urological disorders where muscle spasm contributes to symptoms. By addressing the underlying muscular hyperactivity, Urispas helps restore comfort and control, improving quality of life for those affected by disruptive urinary symptoms.
Features
- Active ingredient: Flavoxate hydrochloride 100 mg per tablet
- Mechanism of action: Direct smooth muscle relaxant with selective action on the urinary tract
- Formulation: Oral tablet for convenient administration
- Prescription status: Available by prescription only, ensuring supervised use
- Manufacturer compliance: Produced under strict pharmaceutical quality standards
Benefits
- Reduces urinary urgency and frequency by calming bladder muscle hyperactivity
- Alleviates pain and discomfort associated with bladder spasms
- Improves bladder capacity, allowing for longer intervals between urination
- Enhances overall quality of life by minimizing sleep disruptions due to nocturia
- Supports management of symptoms related to cystitis, prostatitis, and other urological conditions
- Provides targeted action with minimal effect on other body systems when used as directed
Common use
Urispas is primarily indicated for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence associated with urological conditions such as cystitis, prostatitis, urethritis, and urethrocystitis/urethrotrigonitis. It may be used as monotherapy or as part of a comprehensive treatment plan that includes antibiotics for infectious causes or other medications for chronic conditions. Healthcare providers may prescribe Urispas for both acute episodes and longer-term management of overactive bladder symptoms.
Dosage and direction
The usual adult dosage is one 100 mg tablet three or four times daily. The dosage may be adjusted based on symptom severity and patient response. Tablets should be swallowed whole with a full glass of water, with or without food. For optimal results, doses should be spaced evenly throughout the waking hours. Treatment duration varies depending on the condition being treated; acute conditions may require short-term use while chronic conditions might necessitate longer therapy. Do not crush or chew tablets. Always follow the specific dosing instructions provided by your healthcare provider.
Precautions
Before taking Urispas, inform your healthcare provider if you have any pre-existing medical conditions, particularly glaucoma, gastrointestinal obstruction, urinary retention, or hepatic impairment. Use with caution in elderly patients who may be more sensitive to anticholinergic effects. This medication may cause drowsiness or blurred vision; avoid driving or operating machinery until you know how Urispas affects you. Alcohol may enhance certain side effects and should be limited during treatment. Regular monitoring may be necessary for patients with pre-existing cardiac conditions.
Contraindications
Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It should not be used in patients with gastrointestinal obstruction, paralytic ileus, significant urinary retention, uncontrolled narrow-angle glaucoma, or severe ulcerative colitis. Use is also contraindicated in patients with myasthenia gravis and those with obstructive uropathy. Safety and effectiveness in children under 12 years of age have not been established.
Possible side effects
Common side effects may include dry mouth, blurred vision, drowsiness, dizziness, nausea, vomiting, and nervousness. Less frequently, patients may experience constipation, headache, confusion (particularly in elderly patients), tachycardia, or difficulty urinating. Allergic reactions, though rare, may present as skin rash, itching, or swelling. Most side effects are mild and transient, often diminishing with continued use. Report any persistent or severe side effects to your healthcare provider promptly.
Drug interaction
Urispas may interact with other medications possessing anticholinergic properties, including antihistamines, tricyclic antidepressants, antipsychotics, and other antispasmodics, potentially enhancing side effects. Concurrent use with monoamine oxidase inhibitors (MAOIs) may increase anticholinergic effects. The medication may affect the absorption of other drugs due to its impact on gastrointestinal motility. Always inform your healthcare provider about all prescription medications, over-the-counter drugs, and supplements you are taking before starting Urispas therapy.
Missed dose
If you miss a dose of Urispas, take it as soon as you remember unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining consistent blood levels of the medication is important for optimal symptom control, so try to adhere to the prescribed dosing schedule as closely as possible.
Overdose
Symptoms of overdose may include severe drowsiness, dizziness, blurred vision, dry mouth, difficulty breathing, palpitations, seizures, or loss of consciousness. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is primarily supportive and symptomatic, as there is no specific antidote. Gastric lavage may be considered if ingestion was recent, along with activated charcoal administration. Cardiovascular and respiratory support may be necessary in severe cases.
Storage
Store Urispas tablets at room temperature (15-30°C or 59-86°F) in their original container, protected from light and moisture. Keep the medication out of reach of children and pets. Do not store in bathrooms or other damp areas. Properly discard any expired or unused medication according to local guidelines or through medication take-back programs. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting, stopping, or changing any medication regimen. The prescribing physician should make treatment decisions based on individual patient circumstances. While every effort has been made to ensure accuracy, medical knowledge is constantly evolving, and this information may not reflect the most current research or recommendations.
Reviews
Clinical studies have demonstrated Urispas to be effective in reducing urinary symptoms associated with various urological conditions. In controlled trials, patients reported significant improvement in urgency, frequency, and nocturia compared to placebo. Many healthcare providers consider it a valuable option in the management of bladder spasm-related symptoms, particularly when other treatments are not suitable or require adjunctive therapy. Patient experiences vary, with many reporting improved quality of life and better sleep patterns due to reduced nighttime urination. Some patients note that side effects diminish with continued use, while others may require dosage adjustments for optimal tolerance and efficacy.